KALV:NASDAQKalVista Pharmaceuticals, Inc. Analysis

Technical outlook: KalVista is trading above its 20‑day ($18.24) and 50‑day ($16.82) SMAs, with the 200‑day SMA ($14.50) well below current levels, indicating a sustained bullish trend. The RSI sits at ~58, suggesting momentum is still intact, while the MACD histogram remains positive, reinforcing the bullish bias. Volume is on an upward trajectory, and the price is comfortably above the identified support of $15.09, though the 30‑day volatility of 67% signals sizable short‑term swings.
Fundamental & news backdrop: Recent earnings commentary highlights robust early adoption of the EKTERLY launch, despite heightened operating expenses typical of a new product rollout. The company reports $73.6M in revenue with zero growth and negative margins, yet it holds $300M in cash against $284M of debt, providing a modest liquidity cushion. Forward earnings are projected positive (EPS ≈ $1.01) and the forward P/E of ~19 is well below the industry average of ~26, while analysts assign a “strong buy” rating and price targets near $35‑$36, implying ~77% upside. No dividend is paid, and the balance sheet shows a negative book value per share.